Advance Properties through its 100% owned subsidiary Huvepharma International B.V., plays a significant role on the international market of human and veterinary healthcare products with a focus on livestock.
Huvepharma® is a fast-growing global pharmaceutical company with focus on developing, manufacturing and marketing human and animal health products. These pillars are the basis of our company name Huvepharma® stands for HUman and VEterinary PHARMAceuticals. We place equal emphasis on the creation and marketing of products for livestock and for humans. The company also produces and markets enzymes and nutraceuticals products for different kind of applications.
The highly efficient integrated structure and the talented human capital allow our company to offer competitive and beneficial business conditions. The Huvepharma Group offers premium advantages to its customers and partners, as well as understanding of their needs, which has become an essential component of its continuous growth.
Huvepharma® keeps top quality at all levels, employing highly qualified and experienced specialists in its R&D, production, regulatory affairs, sales and marketing structures.
Huvepharma® operates 11 production sites based in EU and USA. They are GMP certified and where is required are FDA and USDA approved. Our facilities have ISO, HACCP (OVOCOM) and Organic certifications. Our products are part of the food chain, and we are committed to following GMP and HACCP principles to ensure the delivery of safe products to the consumer. The Huvepharma group operates also 2 blending facilities in India and Turkey.
Huvepharma is among the top ten animal health companies measured by revenue, with EUR 588 million revenue for the year ended December 31, 2020 with an established global presence with direct sales teams in all major markets including EU, USA, Canada, Russia, Turkey, Thailand, Taiwan, India, Brazil, Mexico, South Africa, Japan and China.
Today, Huvepharma® is in top 10 largest animal health companies in the world.
In 2019 Huvepharma® ranked #2 in livestock animal health. Huvepharma®’s sales CAGR for the period 2016-2019 is 13% compared to a global animal health CAGR average of 2.5%.
Huvepharma®’s highly profitable growth is realized mostly through organic initiatives by increasing sales of the existing product portfolio and by launching new products developed in-house.
For additional information please visit www.huvepharma.com